RECRUITING Not applicable ClinicalTrials.gov

Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring

Sponsor: University of California, San Francisco • ClinicalTrials.gov ID: NCT07673237

Registry updated: 2026-10-09

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.

Interventions

Spirometer (Device)
Home spirometry will be conducted weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece).
Oximeter (Device)
Oxygen saturation levels will be measured daily using a pulse oximeter.
Scale (Device)
Weight will be measured weekly using a wireless scale provided by the study.
ePROs (electronic patient reported outcomes) (Other)
Brief electronic symptom questionnaires will be completed through a secure app which will be downloaded on participant's phone.

Eligibility criteria

Inclusion Criteria: * age 18 or older * English speaking * have a UCSF diagnosis of one of the major ILD subtypes seen in the ILD Clinic (Idiopathic Pulmonary Fibrosis, Chronic Hypersensitivity Pneumonitis, Connective-tissue disease related ILD, Sarcoidosis, Familial Fibrosis). Languages are limited to those for which both device instructional materials and user support are available (written and video). The ILD diagnosis will be based on multidisciplinary conference review, which is the diagnostic gold standard. We have restricted the ILD subtypes to those for which there is efficacy data for RPM or comparable clinical trajectories, and subtypes that account for \>10% of the ILD diagnoses seen at UCSF. Exclusion Criteria: * Patients who are unable provide informed consent for any reason or are acutely ill.

Conditions

Fibrotic Interstitial Lung Disease IPF and PPF Lung Fibrosis Interstitial

Locations

University of California, San Francisco — San Francisco, California, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment